Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Clinical research trials and Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer. Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "G" Clinical Trials Conditions > Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer



Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

For Condition: Ovarian Cancer,Peritoneal Cancer
Status: Suspended
Sponsor(s): Eli Lilly and Company ,
Synopsis: This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Patients must have disease that can be measured. - Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer. - Patients may only have had one prior platinum-based chemotherapy regimen. - Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days) - Patients must have normal kidney function. Exclusion Criteria: - Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor. - Patients may not have received pelvic or abdominal radiotherapy. - Patients must not have evidence of or received treatment for another cancer within the last 5 years. - Patients must not have been diagnosed with a heart attack in the last 6 months. - Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.
Total Enrollment: 

Location and Contact Information:

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
Atlanta,  Georgia, 
United States
 


Additional Information:
Study ID Numbers:  7127; 
Study Start Date: 
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055432

Other Ovarian Cancer Studies:
1. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

2. Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Related Studies:

Other Ovarian Cancer Clinical Trials
Other Georgia Clinical Trials
Other Atlanta Clinical Trials

Gemzar (gemcitabine) and Alimta (pemetrexed) in the Treatment of Patients with Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Modify your Search

  Other Ovarian Cancer Clinical Trials
  Other Georgia Clinical Trials
  Other Atlanta Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103